Earnings Call · Q2 FY2023·2023-08-08

Q2 23EPS -1.75%·Rev n/aQ1 23EPS -10.45%·Rev n/aQ4 22EPS -100.00%·Rev n/aQ3 22EPS +100.00%*·Rev n/a⚠ consensus missing

ADC Therapeutics SA ADCT

Eugenia Litz — Investor Relations

Ameet Mallik — Chief Executive Officer

Kristen Herrington-Smith — Commercial Leader / Sales Leader

Mohamed Zaki — Chief Medical Officer

Pepe Carmona — Chief Financial Officer

+11.9%1d on move date+12.3% vs SPY3d+12.6%5d+10.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ADCT calls or request research access.

More ADCT calls Browse calls Request research access